A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of intraseasonal specific short-term immunotherapy with depigmented glutaraldehyde polymerized birch pollen allergenic extract (Depiquick Birch) in patients with allergic rhinitis and/or rhinoconjunctivitis with or without intermittent asthma.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms INSIDE
- 22 Mar 2017 Biomarkers information updated
- 18 Jul 2013 New source identified and integrated (ClinicalTrials.gov record, NCT01902992).
- 29 Oct 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.